Literature DB >> 7264623

The effects of lisuride and some other dopaminergic agonists on receptor binding in human brain.

G P Reynolds, P Riederer.   

Abstract

The effect of lisuride, bromocriptine, CQ 32-084 and CU 32-085 on the specific binding of radiolabelled spiperone to homogenates of human putamen taken post-mortem has been investigated. In addition, the binding of 3H-lisuride to such preparations has been studied. Lisuride is found to inhibit spiperone binding to the dopamine receptor at very low concentrations and to bind to the beta-adrenergic receptor at somewhat higher levels. Lisuride binding to the dopamine receptor was found to be antagonist-like. A measure of the in vivo effect of lisuride was obtained from investigations of brain tissue taken from a patient treated with the drug before death.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264623     DOI: 10.1007/BF01664008

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  9 in total

1.  Association of high affinity stereospecific binding of 3H-propranolol to cerebral membranes with beta adrenoceptors.

Authors:  S R Nahorski
Journal:  Nature       Date:  1976-02-12       Impact factor: 49.962

2.  Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice.

Authors:  R Horowski; H Wachtel
Journal:  Eur J Pharmacol       Date:  1976-04       Impact factor: 4.432

3.  Bromocriptine in Parkinson's disease.

Authors:  K M Shaw; A J Lees; G M Stern
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

4.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

5.  Lisuride inhibits 3H-spiroperidol binding to membranes isolated from striatum.

Authors:  N Fujita; K Saito; N Yonehara; H Yoshida
Journal:  Neuropharmacology       Date:  1978-12       Impact factor: 5.250

6.  Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain.

Authors:  W Kehr
Journal:  Eur J Pharmacol       Date:  1977-02-07       Impact factor: 4.432

7.  Lisuride hydrogen maleate: an ergoline with beta-adrenergic antagonist activity.

Authors:  T Cote; M Munemura; J Kebabian
Journal:  Eur J Pharmacol       Date:  1979-11-16       Impact factor: 4.432

8.  Lisuride in parkinsonism.

Authors:  J D Parkes; M Schachter; C D Marsden; B Smith; A Wilson
Journal:  Ann Neurol       Date:  1981-01       Impact factor: 10.422

9.  Increased dopamine-receptor sensitivity in schizophrenia.

Authors:  F Owen; A J Cross; T J Crow; A Longden; M Poulter; G J Riley
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

  9 in total
  1 in total

1.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.